Melbourne, Victoria--(Newsfile Corp. - May 22, 2025) - Besra Gold Inc. (ASX: BEZ) ("Besra" or the "Company") is aware of certain information related to Besra and its business that was provided as part of a presentation (the Unauthorised Presentation) made on behalf of Quantum Metal Bullion Pty Ltd (Quantum Metal). Quantum Metal is a company associated with Dato Lim Khong Soon, a director of Besra.The Unauthorised Presentation, which the Company is aware has been presented several times online, contains:(a) ...

Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) – – No relapses recorded to-date; no safety signals identified – – Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center – – KOL ev ...

MARYSVILLE, Ohio, May 22, 2025 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded consumer lawn and garden as well as a leader in indoor and hydroponic growing products, will participate in the William Blair 45th Annual Growth Stock Conference in Chicago on Thursday, June 5, 2025. President and Chief Operating Officer Nate Baxter and Chief Financial Officer Mark Scheiwer will be among the featured speakers at the conference, discussing current business st ...

HOUSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") announced today that Dan Schlanger, Crown Castle’s Interim President and Chief Executive Officer, and Sunit Patel, Crown Castle’s Executive Vice President and Chief Financial Officer, are scheduled to present on Wednesday, June 4, 2025 at 2:45 p.m. Eastern Time at Nareit’s REITweek: 2025 Investor Conference. The presentation will be broadcast live over the Internet and is expected to last approximately 30 minutes. The l ...

SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC today announced that Rich Steinmeier, Chief Executive Officer, will present at the Bernstein Strategic Decisions Conference on May 28. The presentation takes place at 8 a.m. ET. A live audio webcast of the presentation will be accessible at investor.lpl.com, with a replay available on the website after the presentation. Contacts Investor Relationsinvestor.relations@lplfinancial.com Media Relationsmedia.relations@lplfinancial.com About LPL Financi ...

In connection with the first quarter 2025 report released earlier today, IDEX Biometrics CEO Anders Storbråten will host a presentation at Arctic Securities at 12:00 CET today. The presentation is attached. For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@idexbiometrics.com About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital ide ...

Details for the Late-Breaking Clinical Trial Abstract: | Abstract | Phase 3 Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor in Patients with | | --- | --- | | Title: | Uncontrolled and Treatment-Resistant Hypertension: Launch-HTN Study | | Presenter: | Manish Saxena MBBS, Hypertension Specialist from Barts Health NHS Trust and William Harvey Heart Centre, Queen Mary University London | | Session Date/Time: | Saturday, May 24th, at 10:00-11:00am CEST | | Session | Late Breakers 1 | | Title: | | ...

HOLMDEL, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless, Identity-Bound Biometric (IBB) authentication solutions today announces its participation at the Aegis Capital Corp. 2025 Virtual Conference on Thursday, May 22nd and the Maxim Virtual Tech Conference on Wednesday, June 4th – webcast access details provided below. Aegis Cap ...

Core Insights - Acoramidis has shown significant clinical benefits in reducing the incidence of atrial fibrillation (AF) and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][4][5] - The drug has received regulatory approvals in multiple regions, including the U.S. and Europe, indicating its potential as a treatment option for ATTR-CM [1][6] Group 1: Clinical Outcomes - In a post-hoc analysis of the ATTRibute-CM study, acoramidis reduced the annual frequency of cardiovascular hospitalizations (CVH) due to AF/atrial flutter (AFL) by 43% compared to placebo [1][4] - The incidence of new-onset AF/AFL was reduced by 17% in patients with no prior history of AF when treated with acoramidis [1][4] - A 42% reduction in composite all-cause mortality (ACM) and recurrent CVH events was observed at Month 30 relative to placebo [3] - Acoramidis treatment led to a greater than 50% reduction in ACM and CVH in participants with variant ATTR-CM compared to placebo [7] Group 2: Functional Capacity and Quality of Life - Patients with variant ATTR-CM treated with acoramidis showed a clinically significant slower decline in functional capacity and quality of life compared to placebo [7] - At Month 30, the mean difference in the 6-minute walk distance was 86.7 meters in favor of acoramidis (p = 0.0048) [7] - The KCCQ-OS score change from baseline at Month 30 was 20.3 points higher in the acoramidis group compared to placebo (p = 0.0019) [7] Group 3: Regulatory Approvals and Future Directions - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission and other regulatory agencies [1][6] - The company plans to present more data on the benefits of acoramidis for ATTR-CM patients at future medical meetings [6]

Investor Presentation - Financial Results Q1 2025 Attachments Q1 2025 Investor Presentation Q1 2025 Investor Presentation ...